<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-17T19:41:46.622Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-17T19:41:46.622Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-17T19:41:46.622Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-17T19:41:46.622Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-17T19:41:46.622Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/GSK:1794942153000</loc>
    <lastmod>2026-11-17T19:02:33.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GSK/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>FDA Grants Accelerated Approval to GSK&#39;s Nelkarmi for ALK-Positive Lung Cancer</image:title>
      <image:caption>The FDA granted accelerated approval to GSK’s Nelkarmi for patients with ALK-positive lung cancer, allowing its immediate use in this population. The approval expands GSK’s oncology portfolio; the article reports no financial figures or stock-market impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BILL:1794942152000</loc>
    <lastmod>2026-11-17T19:02:32.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BILL/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>TPG Nearing Acquisition Deal for BILL Holdings</image:title>
      <image:caption>TPG is reportedly in advanced discussions to acquire BILL Holdings, with a deal nearing agreement, according to financial news outlets including the Financial Times. No final terms have been disclosed, and BILL has not officially confirmed the potential acquisition. The report provides no financial figures or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BMNR:1794942110000</loc>
    <lastmod>2026-11-17T19:01:50.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BMNR/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Bitmine Immersion Technologies Reports $11.8 Billion in Total Crypto and Liquid Assets</image:title>
      <image:caption>Bitmine Immersion Technologies reported total crypto and liquid assets of $11.8 billion as of November 17, 2026, including 6.08 million ETH tokens. It said 5,227,037 ETH are staked on its MAVAN platform and that its holdings represent 4.97% of the total ETH supply, or 99% of its “Alchemy of 5%” goal. The company continues weekly ETH acquisitions and described itself as the world’s largest publicly traded Ethereum treasury company.</image:caption>
    </image:image>
  </url>
</urlset>